
OSTEOARTHRITIS and CARTILAGE

Preface

BY G. MAUTONE AND E. TAJANA

R & D Department, IBSA, Institut Biochimique SA, Lugano, Switzerland

THIS Supplement contains the papers presented at the Satellite Symposium organized by IBSA (Switzerland) and Laboratoires Genevrier (France): 'Chondroitin Sulfate: Update in Osteoarthritis', held on June 8 1997 in Singapore on the occasion of the OARS Congress. Condrosulf[®] was developed by IBSA and is now available on the market in several European countries: Austria, Czech Republic, France, Hungary, Italy, Slovak Republic and Switzerland. In the course of the Symposium, co-chaired by R. D. Altman (Miami, Florida), B. A. Michel, (Zurich, Switzerland) and E. Vignon (Lyon, France), a group of investigators

presented up-to-date pharmacological results, as well as those deriving from medium and long-term clinical trials, mostly performed in accordance with the International Agreements of the Osteoarthritis Research Society. We would like to express our grateful thanks to all the authors and the three co-chairmen who presided over the Symposium and led the discussion for their precious participation.

Acknowledgments

We would like to express our gratitude to S. Rovati (R&D Department, IBSA) for his scientific contribution. We are also much indebted to D. Vacher (Managing Director, Laboratoires Genevrier), M. J. Bouliane, J. Bugeaud, A. E. Lugin (Marketing Department, Laboratoires Genevrier), and O. Bardelli (R&D Department, IBSA) for their consistent support and fruitful collaboration in organizing this Symposium and for the success of the social program.

Address correspondence and reprints requests to: G. Mautone, R&D Manager, IBSA, Institut Biochimique SA, 6903 Lugano, Switzerland.

Supplement sponsored by IBSA (Switzerland)/Laboratoires GENEVRIER (France).